N@N

RXi Pharmaceuticals to Webcast Presentation at the Lazard Capital Markets Annual Healthcare Conference

^{Published on 2010-11-10 06:40:34 - Market Wire}
 

WORCESTER, Mass.--([ BUSINESS WIRE ])--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Companya™s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the Lazard Capital Markets 7^th Annual Healthcare Conference on Wednesday November 17, 2010 at 2:45 ET in New York City.

A live webcast of the presentation will be available from the aInvestor Relationsa section of the Company's website, [ www.rxipharma.com ]. A replay of the presentation will be available for 30 days.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both RNA interference (RNAi) compounds and delivery methods. The company is leveraging this broad and integrated RNAi therapeutic platform to build a pipeline of RNAi therapeutics for the treatment of a number of disease areas, including its core focus of developing treatments for anti-scarring and retinal disorders as well as a continued interest in oncology and indications accessible by spinal cord delivery. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi therapeutics market based on the strength of its next generation therapeutic platform, experienced management team, accomplished Scientific Advisory Board, including Nobel Laureate, Dr. Craig Mello, and its broad intellectual property position in RNAi chemistry and delivery. [ www.rxipharma.com ]